Relative potencies and equivalent doses of representative corticosteroids
Corticosteroids are group of hormones with similar chemical formulas which are secreted by adrenal cortex. The very slight differences in molecular structure of various corticosteroids give them very different functions. The hormonal steroids are classified according to their biologic effects as glucocorticoids, which mainly affect intermediary metabolism and the immune system, and mineralocorticoids, which have principally a salt-retaining activity. Of large number of steroids released into the circulation by adrenal cortex, two are of greater importance – aldosterone, which is a mineralocorticoid, and cortisol, which is a glucocorticoid.
Mineralocorticoids promote sodium and water retention, and potassium loss by kidney, but have no anti-inflammatory or anti-allergic effect.
Cortisol, also known as hydrocortisone, is the major glucocorticoid in humans. It is synthesized by the cells of the zona fasciculata and zona reticularis of adrenal cortex; its secretion is regulated by the adrenocorticotropic hormone (ACTH) from anterior pituitary gland. Cortisol has a wide range of physiologic actions such as influencing carbohydrate, protein, and fat metabolism; regulation of blood pressure and cardiovascular function; and affecting immune system.
Corticosteroid drugs are the synthetic analogs of cortisol hormone. They bind to specific intracellular receptors upon entering target tissues, and mimic the effects of the naturally occurring hormones; the main differences are the relative glucocorticoid versus mineralocorticoid potency and the long half-life that the synthetic analogs have. The relative potencies and duration of action of representative corticosteroids are presented in Table 1.
Glucocorticoids are used, either singly or in combination with other drugs, in the treatment of a wide variety of medical disorders. Some therapeutic indications for these drugs are as follows:
Musculoskeletal and connective tissue diseases (rheumatoid arthritis, polymyositis, systemic lupus erythematosus, and vasculitis)
Respiratory diseases (sarcoidosis and chronic bronchitis)
Gastrointestinal diseases (ulcerative colitis and crohn's disease)
Allergic disorders (asthma, hay fever, and allergic rhinitis)
Skin conditions (pemphigus, eczema, and dermatitis)
Eye diseases (conjunctivitis, uveitis, and optic neuritis)
Oral and maxillofacial diseases (lichen planus, keloid formation, and Bell's palsy)
Although corticosteroids are widely used for treatment of diseases and conditions affecting oral and maxillofacial region, the scientific literature on this topic is limited and scattered throughout numerous journals and books. By gathering this scattered information, this chapter presents a concise review of various uses of corticosteroid drugs in the treatment of diseases affecting oral and maxillofacial region, and the role they have in reducing post-operative morbidities such as pain, edema and trismus after various maxillofacial surgical procedures. The relation between maternal corticosteroid use and congenital maxillofacial deformities are explained. Also discussed is the perioperative management of patients receiving long-term therapeutic doses of corticosteroids.
2. Uses of corticosteroids in the treatment of oral and maxillofacial diseases
Corticosteroids are widely used in the treatment of diseases, disorders and conditions affecting the oral and maxillofacial area and the adjacent and associated structures. The diseases of the oral and maxillofacial region may be either local or the manifestation of a systemic problem. Corticosteroids have their widest application in the management of acute and chronic conditions which have an allergic, immunologic, or inflammatory basis. Therefore, a group of corticosteroids which have predominantly a glucocorticoid activity and little or no mineralocorticoid action such as betamethasone, dexamethasone, triamcinolone, and prednisolone are used.
The following are the main therapeutic indications for glucocorticoids in oral and maxillofacial diseases.
2.1. Temporomandibular disorders (TMDs)
TMDs are clinical problems involving the temporomandibular joints (TMJs), the masticatory muscles, or both. TMDs affect a significant number of individuals, and are the most common musculoskeletal disorders that cause orofacial pain.  Trauma to the joint structures, especially microtrauma, accounts for the majority of patients who develop TMJ problems. However, a small number of joint diseases are caused by nontraumatic etiologic factors including benign and malignant neoplasms (osteoma, chondroma, and synovial sarcoma), congenital or developmental anomalies (condylar agenesis and heperplasia), arthritides (rheumatoid arthritis), and systemic diseases. The most common signs and symptoms of TMDs are pain, altered mandibular movements, and the elicitation of joint noise.
Treatment of TMDs varies according to their etiologic basis. Conservative managements (splint therapy, thermal application, pharmacotherapy, and physiotherapy), surgical treatments, or a combination of them may be required. A variety of medications have been used to relieve pain, inflammation, muscle spasm and other signs and symptoms associated with TMDs. They include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, analgesics, and muscle relaxants.
Various glucocorticoids are used in the treatment of TMDs (Table 2). These drugs have dramatic effects on pain, hypomobility, and inflammation associated with acute TMJ problems. Oral corticosteroids are used mainly for treatment of acute TMJ discomforts or for diagnostic purposes. They should be used in a short term basis (tapering dose lasting 5 to 7 days), and repeated as infrequently as possible. Long term use of corticosteroids for the treatment of TMDs is contraindicated; it can result in a cushing's- like disease process, acute adrenal crisis, hypertension, electrolyte abnormalities, diabetes, and formation of osteoporosis including the TMJ. 
|Prednisone||Deltasone, Orasone||5-60 mg/day|
Intracapsular injection of glucocortcoids has been reported to decrease pain in patients with both pain and limited mouth opening secondary to inflammatory disorders of the joint, such as arthritis and capsulitis. [3-5]
A number of mechanisms have been described for the anti-inflammatory actions of glucocorticoids. These drugs inhibit inflammatory mediator release from many cell types involved in inflammation such as macrophages, T-lymphocytes, mast cells, dendritic cells, and neutrophilic leukocytes. Glucocorticoids also reduce prostaglandin production by blocking the phospholipase A2 enzyme.
The most striking effect of glucocorticoids is to inhibit the expression of multiple inflammatory genes encoding cytokines, chemokines, inflammatory enzymes, receptors and adhesion molecules.  Changes in gene transcription are regulated by proinflammatory transcription factors, such as nuclear factor-κB (NF-κB) and activator protein-1 (AP-1). These proinflammatory transcription factors switch on inflammatory genes via a process involving recruitment of transcriptional coactivator proteins and changes in chromatin modifications such as histone acetylation. Glucocorticoids exert their anti-inflammatory effect on responsive cells by binding and activating a cytoplasmic glucocorticoid receptor. The interaction between the activated glucocorticoid receptor and proinflammatory transcription factors may result in deacetylation of histones and repression of inflammatory genes. 
In chronic inflammatory disorders of TMJ, macrophages, T-lymphocytes, and other cell types involved in inflammation release many cytokines and chemokines which will induce expression of adhesion molecules, release of variable enzymes from fibroblasts and osteoclasts and result in bone erosion. IL-8, which is a chemokine, is known to cause the infiltration of neutrophils into synovial fluid and promote joint inflammation. It was detected in 80% of the synovial tissue specimens taken from the TMJs with internal derangement. Similarly, IL-11 has been involved in the pathogenesis of osteoarthritis and rheumatoid arthritis. It has been found in synovial fluids of diseased temporomandibular joint and other joints. 
Cytokines participate in various inflammatory processes and induce protease synthesis; their effects can be either synergic or inhibitory. In synovial joints, IL-1
Long-term complications associated with intra-articular glucocorticoid injection cannot be determined from the limited investigations done to date and thus remained unclear. Wenneberg et al. in a study evaluating the long-term prognosis of intra-articular glucocorticoid injections for TMJ arthritis observed that this treatment modality was helpful, and there were no radiographically demonstrable side effects of the treatment.  In contrast, Haddad IK showed that intra-articular injections of corticosteroids (triamcinolone acetonide) cause damage to fibrous layer, cartilage, and bone of TMJ. 
Juvenile idiopathic arthritis (JIA) is a chronic rheumatologic disease of children which may involve TMJ region, and cause significant craniofacial growth disturbances. The treatment of TMJ arthritis is controversial. It has been shown that glucocorticoid injection of the TMJ reduces pain and inflammation, and improves the function of TMJ in children with JIA.  Other studies also confirmed that corticosteroid injection of the TMJ can be safely performed in children with JIA, and is effective. [15-18] Few studies have evaluated TMJ corticosteroid injection in JIA. In these studies the volume of corticosteroid injected was chosen empirically. Treatment protocols such as injection of 1 cc (40 mg) of triamcinolone acetonide, 1 cc (20 mg) of triamcinolone hexacetonidein, and 0.5 to 1 cc of the diluted (with 1% lidocaine HCL) triamcinolone hexacetonidein into each of the involved TMJs, all have been used in previous studies. [14-16] The peak effect occurs after approximately 6 weeks of treatment, and the expected duration is 6-17 months. The children may receive a second injection approximately 6 months after the first. 
Side effects of intra-articular steroid injection in children include immediate reactions, such as pain and headache, or delayed side effects, such as joint infection and loss of subcutaneous fat.  Because the mandibular endochondral growth zone is located at the head of condyle (at the site of corticosteroid injection), the concern is whether intra-articular corticosteroid injection per se may cause growth retardation. Stoustrup et al., in an animal study demonstrated that intra-articular glucocorticoid injection may result in even more pronounced mandibular growth reduction than that caused by the arthritis alone.  Schindler et al. reported a case of severe temporomandibular dysfunction and joint destruction after intra-articular injection of triamcinolone, and El-Hakim et al. showed TMJ resorption with active osteoclastic activity after intra-articular injection of a single dose of dexamethasone in rats. [20,21]
intra-articular corticosteroid injection has been used to improve mouth opening in patients with anterior disk displacement without reduction (ADDWOR), i.e., closed lock. 
2.2. Oral ulcerative and vesiculobullous lesions
Corticosteroids are successfully used for the treatment of several ulcerative and vesiculobullous lesions involving the oral cavity and perioral areas including recurrent aphthous stomatitis (RAS), Behcet's syndrome, pemphigus vulgaris, bullous pemphigoid, mucous membrane pemphigoid, erythema multiforme and Stevens-Johnson syndrome (Tables 3-5). 
Topical and injectable (intralesional) corticosteroids are useful for large and painful lesions. Systemic administration of corticosteroids is reserved for severe cases to prevent lesion formation or to reduce the number of lesions. Systemic corticosteroids should be prescribed in short courses, and only for severe outbreaks or cases that don't respond to topical or injectable corticosteroids. 
The principal treatment of pemphigus vulgaris is systemic administration of corticosteroids at doses of 1 to 2 mg/kg/day. Maintenance of remission may be achieved with topical corticosteroids, allowing reduction of systemic drugs. Isolated lesions can be treated with injectable corticosteroids. 
|Indications||Severe recurrent aphthous stomatitis,|
|major aphthous stomatitis, erosive lichen planus|
|Usual dosage||Inject 0.1 cc/cm lesion|
|Contraindications||Hypersensitivity to corticosteroids, systemic fungal infection, live vaccines, active tuberculosis|
|Common side effects||Candidiasis, hyperglycemia|
|Unusual side effects||Peptic ulceration with perforation, osteoporosis, impaired wound healing, mucosal atrophy|
|Indications||Severe recurrent aphthous stomatitis, Behcet's syndrome, pemphigus vulgaris, pemphigoid|
|Administration||Inhaler spray topically to mucosal lesions||Topical intraoral cream or gel, soluble tablets as mouth wash||Topical intraoral cream or gel||Topical intraoral cream or ointment||Topical intraoral cream|
|Usual dosage||50-100 µg sprayed onto oral lesion||0.1% cream or 0.05% gel applied thinly bid; 0.5 mg 2-4 times daily as mouth wash||0.05% cream or gel applied thinly bid||0.05% cream or ointment applied thinly bid||0.05% cream applied thinly bid|
|Common side effects||Oral candidiasis|
|Unusual side effects||Adrenal suppression if doses exceeded|
|Indications||Severe recurrent aphthous stomatitis, Behcet's syndrome, pemphigus vulgaris, pemphigoid, erythema multiforme|
|Usual dosage||1. 30-40 mg daily after breakfast for 4-5 days 2. 1-2 mg/kg/day after breakfast until disease controlled 3. 1-2 mg/kg/day, then maintenance of 2.5-15 mg daily 4. 20-40 mg daily for 7-10 days at onset of lesions or until lesions resolve 5. 60 mg daily for 2 days, 50 mg daily for 2 days, 40 mg daily for 2 days, 30 mg daily for 2 days, 20 mg daily for 2 days, 10 mg daily for 2 days|
|Contraindications||Hypersensitivity to corticosteroids, systemic infection (unless specific antimicrobial therapy given), peptic disease (unless proton pump inhibitor given), live vaccines|
|Common side effects||Dyspepsia, candidiasis, myopathy, osteoporosis, adrenal suppression, Cushing's syndrome, euphoria, depression|
|Unusual side effects||Peptic ulceration with perforation, Cushingoid side effects increasingly likely with doses above 7.5 mg daily|
2.3. Keloid and hypertrophic scars
Keloid and hypertrophic scar (HS) represent pathologic overhealing conditions which are caused by excessive production of fibrous tissue following healing of skin injuries. Keloid produces significantly more collagen than HS. Their exact cause is unknown but inflammation, tension, and genetic background are mentioned as contributing factors. Keloid and HS have different clinical features. Keloids extend beyond the confines of the original wound, develop months after injury, and rarely regress. HS is a raised scar that remains confined to the area of the injury, usually form within weeks, and may regress without intervention.
Various treatment modalities have been used for prevention and treatment of keloid and HSs such as pressure therapy, silicone gel sheeting, topical flavonoids, corticosteroid therapy, radiotherapy, and surgery.
Topical and intralesional glucocorticoids are frequently used to treat existing keloid and HS or, prophylactically, to prevent their formation or recurrence after surgical removal. Topical administration of steroids doesn't appear to be as efficacious as intralesional injection of the drug. Intralesional steroid injection, either on its own or in combination with other treatment modalities is the most common treatment used for keloid and HSs. Glucocorticoids have a multiplicity of effects on scars including suppressive effects on the inflammatory process in the wound, diminishing collagen and glycosaminoglycan synthesis, inhibition of fibroblast growth, and enhancing collagen and fibroblast degeneration. [40,41] Triamcinolone acetonide is the most commonly used steroid for the treatment of HS and keloid. It is used in a concentration of 10-20 mg/ml, though it can be given at a dose of 40 mg/ml for a tough bulky lesion; the concentration depends upon the size and site of the lesion and age of the individual.  Side effects of steroid injection include hypopigmentation, dermal atrophy, telangiectasia, and cushingoid effects from systemic absorption.  Cushing's syndrome secondary to injection of triamcinolone acetonide for the treatment of keloids have been reported by several investigators. [43,44]
2.4. Central giant cell granuloma
Central giant cell granuloma of the jaws is a benign tumor which occurs most often in children and young adults. This tumor is made up of loose fibrous connective tissue stroma with many interspersed proliferating fibroblasts, aggregations of multinucleated giant cells, and foci of hemorrhage.
Various surgical and nonsurgical treatments have been advocated for this lesion. One of the nonsurgical treatments proposed is intralesional corticosteroid injections. Intralesional injection of triamcinolone acetonide has been shown to induce partial and in some cases complete resolution of central giant cell granuloma. However, there is no reasonably strong consensus in the literature regarding optimal dosage and duration of treatment that provides the most benefit. The mechanism of action of corticosteroids in the treatment of central giant cell granuloma is unknown. A rationale for its use has been the histologic resemblance of central giant cell granuloma to sarcoid. Because corticosteroids have been effective in the treatment of sarcoid, it was thought that they may have a similar therapeutic effect on central giant cell granuloma. In addition, corticosteroids may act by suppressing any angiogenic component of the lesion. 
2.5. Bell's palsy
Bell's palsy is an idiopathic inflammation of the facial nerve (the seventh of twelve paired cranial nerves) which occurs almost always on one side only. It is characterized by facial muscle weakness, hyperacusis, decreased tearing, and loss of taste on the anterior two thirds of the tongue. Because Bell's palsy results from inflammation and edema of the facial nerve, corticosteroids constitute the standard medicine in the treatment of this condition. [46-48] For adults, prednisolone at doses of 1 mg/kg/day for 7 to 10 days, taken in divided doses in the morning and evening, is suggested.
2.6. Management of post-operative morbidities associated with maxillofacial surgeries
Facial pain, edema, ecchymosis and limitation of mouth opening are the expected sequelae of oral and maxillofacial surgeries. These post-operative complications affect the ability of patient to interrelate and to return to the daily life and activities, and deteriorate the quality of life of patient. [49,50]
Many modalities are used to abate sequelae in the oral and maxillofacial surgery including use of ice pack, pressure dressing, surgical drain, and drugs.
Corticosteroids are commonly used to control post-operative morbidities and to provide comfort for patients. However, there are no definite protocols relative to molecules, doses, schedules, and routes of administration.  The most commonly administered types of corticosteroids are betamethasone, dexamethasone, and methylprednisolone, administered intravenously, orally or by injection into the masseter muscle. The morbidity-management protocol also varies depending upon the type of surgery being performed.
To decrease post-rhinoplasty edema, the administration of corticosteroids has been advocated for many years. In a study by Gurlek et al., it was shown that high dose methylprednisolone was effective in preventing and reducing both the periorbital ecchymosis and edema in open rhinoplasty.  In the same line, Kargi et al., and Kara and Gokalan showed that the perioperative use of corticosteroids reduced edema and ecchymosis associated with rhinoplasty surgery. [53,54] In contrast, Hoffmann et al. did not observe any increase either in the edema or the ecchymosis after rhinoplasty surgery. 
Regarding orthognathic surgery, several investigations demonstrated that perioperative corticosteroid administration significantly reduced post-operative inflammation and edema. [56-59] In contrast, Munro et al. did not observe any significant decrease in postoperative edema even with the highest doses and the longest durations of corticosteroid treatment. (56)
The effects of corticosteroids on post-operative edema after oral surgery have been widely investigated in the literature. Many prior studies demonstrated a significant decrease in post-operative edema after administration of corticosteroids. [60-63] In a study by Zandi, it was shown that steroids not only reduced the facial swelling, but also the severity of pain after surgery.  Similarly, several studies reported that corticosteroids significantly decreased post-operative edema and pain, indicating a strong correlation between edema and pain decreases. [62-64]
Even though the effects of corticosteroids on post-operative morbidities after various oral and maxillofacial surgeries have been widely investigated in the literature, methodological differences, variation in agents, doses, and routes of administration of the drugs have compromised the scientific conclusions.
2.7. Other uses of corticosteroids in oral and maxillofacial surgery
In addition to the aforementioned indications, corticosteroids are successfully used in the management of acute trigeminal nerve injuries, traumatic facial nerve paralysis, chronic facial pain, and allergic diseases involving maxillofacial area.
3. Corticosteroids contraindications
In prescribing corticosteroids, physicians must be aware that some patients are poor candidates for systemic, locally injected, or topical corticosteroid therapy.
Systemic corticosteroids must be used with the greatest of caution in patients with uncontrolled hypertension, diabetes, active peptic ulcer, heart diseases, infections, psychiatric disorders, osteoporosis, cataract, glaucoma, tuberculosis, mycobacterial diseases, herpes simplex infection, pregnancy, varicella zoster infection, immune deficiency, underactive thyroid, and mental disorders.
Injectable corticosteroid use is contraindicated in patients with hypersensitivity to corticosteroids, infections, and active tuberculosis.
Use of topical corticosteroids is absolutely contraindicated in the treatment of primary bacterial infections such as impetigo, furuncles, carbuncles, erysipelas, cellulitis, lymphangitis, and erythrasma. Topical corticosteroids are also contraindicated in patients with a history of hypersensitivity to any of the components of the preparation. Currently, little is known about the safety of topical corticosteroids in pregnancy. Although it has been reported that there is an association between very potent topical corticosteroids and congenital abnormalities including low birth weight and orofacial clefts, use of these drugs in pregnancy is not recommended unless the potential benefit justifies the potential risks to fetus. 
Ophthalmic use of topical corticosteroids is contraindicated in most viral, bacterial, and fungal diseases of ocular structures.
4. Corticosteroids side effects
Although corticosteroids have great potential in the treatment of various diseases and conditions affecting oral and maxillofacial region, they also carry the risk of many side effects. Therefore, benefits from corticosteroids should always be weighed against their potential risks. Side effects of corticosteroids vary depending on the type and dose of the medication, rout of administration, and length of treatment. Significant adverse effects are most likely to occur in patients using oral corticosteroids for a long period of time. These may include weight gain, impaired growth, adrenal insufficiency, electrolyte abnormalities, increased susceptibility to infection, myopathy, osteoporosis, osteonecrosis, cataract, glaucoma, psychological problems, fractures, hypertension, insomnia, moon face, diabetes, and peptic ulcer. [1,66]
Topical glucocorticoids may cause adverse effects such as skin atrophy, hypopigmentation, subcutaneous fat wasting, telangectasia, contact dermatitis, oral thrush, and cushingoid effects from systemic absorption. [28,41] Application of topical corticosteroids on eyelids has been reported to cause glaucoma. Adrenal suppression, growth retardation in children, and cushing's syndrome are rare adverse effects of long term topical corticosteroid use.
Intralesional glucocorticoids may cause sterile abscess, skin atrophy, hypopigmentation, panniculitis, and skin necrosis.
Although the frequency of side effects of inhaled corticosteroids is lower than systemic corticosteroids, high doses of inhaled corticosteroids have the potential to produce various local and systemic side effects. Systemic side effects associated with inhaled corticosteroids
include osteoporosis, retarded growth in children, cataracts, glaucoma, and skin thinning. Inhaled corticosteroids may cause local side effects including oropharyngeal candidiasis, dysphonia, reflex cough, bronchospasm, and pharyngitis. 
5. Perioperative management of patients with adrenal insufficiency
Insufficient adrenocortical function is a rare disorder resulting from endogenous deficiency (primary) or from the administration of exogenous corticosteroids (secondary). Adrenal suppression should be suspected in those patients receiving the equivalent of 20 mg of prednisone daily for one week or the equivalent of 7.5 mg of prednisone daily for one month within the past year.  In adrenal suppression the body is not able to appropriately manage the challenge of stresses such as medical illness, surgery, and trauma. This may precipitate an adrenal crisis, signaled by the onset of fever, restlessness, flank and abdominal pain, vomiting, lethargy, hypotension, or coma.
Any patient suspected of having adrenal insufficiency should be evaluated with an ACTH (cortrosyn) stimulation test or be given supplemental corticosteroids empirically perioperatively. Cortrosyn stimulation test measures how well the adrenal glands respond to a synthetic ACTH administered to the patient.
The currently recommended corticosteroid coverage for various surgical procedures is based on the magnitude of stress and the known glucocorticoid production rate associated with it, and includes the following: [2,68]
Minor surgical stress such as tooth extraction, biopsy, periodontal surgery, genioplasty, etc: 25 mg of hydrocortisone equivalent, the day of surgery
Moderate surgical stress such as panfacial fractures, two jaw surgery, etc: 50-75 mg of hydrocortisone equivalent for 1 to 2 days.
Major surgical stress such as extensive head and neck resection and reconstruction, etc: 100-150 mg of hydrocortisone equivalent for 2 to 3 days.
In the case of postoperative complications such as fever and pain, it is recommended that the corticosteroid administration be continued consistent with the post-operative stress response. 
6. Maternal corticosteroid use and the risk of orofacial clefts in infants
Orofacial clefts are the most common congenital deformity affecting maxillofacial area. The etiology of facial clefting is complex and has been extensively investigated. There are both major and minor genetic influences involved, with variable interactions from environmental factors.  Several environmental factors such as maternal drug intake, trauma, smoking, and exposure to x-rays during the pregnancy period have been suggested to increase the chance of cleft development in infants. 
Pregnant women often use topical, inhaled, or systemic corticosteroid drugs for a variety of inflammatory and allergic conditions. Several investigations have reported that the use of corticosteroids during early pregnancy is associated with a 3- to 6-fold increased risk of orofacial clefts. [71-75] Although systemic corticosteroids are associated with a higher risk of orofacial clefts than topical corticosteroids, the latter is not without risk. It has been shown that application of hydrocortisone cream on eczematous skin is associated with significant increase in the level of plasma cortisol.  In a study by Edwards et al., a significant association between topical corticosteroids and orofacial cleft was observed.  Epidemiologic data have shown that low-to-moderate doses of inhaled corticosteroids taken during the first trimester of pregnancy are safe but raise concerns about high doses. 
The mechanism of cleft palate production by corticosteroids is uncertain; it is a complicated interference in a complex developmental program involving many genetic and biochemical processes. Glucocorticoids may cause cleft palate deformity by delaying palatal shelf elevation.  Corticosteroids can reduce the collagen content of connective tissue by inhibiting collagen synthesis, which could disrupt cell-cell interaction and tissue-tissue interactions. 
Glucocorticoids are used, either singly or in combination with other drugs, for the treatment of various diseases affecting oral and maxillofacial area. They are also frequently used to minimize expected post-operative morbidities such as pain and edema after oral and maxillofacial surgeries. Because of anti-inflammatory and anti-allergic actions of glucocorticoids, they have their widest application in the management of acute and chronic conditions which have allergic, immunologic, or inflammatory basis. However, corticosteroids carry the risk of potential side effects which are sometimes severe and life threatening. Therefore, benefits from corticosteroids should always be weighed against their potential risks in each patient.
Prescribing the minimal dose and the least potent type of corticosteroids necessary to produce a given therapeutic effect, simultaneous use of non-steroidal agents to reduce the dose of corticosteroids, and prescribing corticosteroids for a short period of time or sporadically are some strategies to minimize corticosteroids adverse effects.
The author wishes to express his deep appreciation to Dr. Mojgan Ahmadian for her extensive assistance in the preparation of this chapter.
Brunton LL, Lazo JS, Parker KL 2005 Goodman & Gilman’s The pharmacological basis of therapeutics. Eleventh edition. New York: McGraw-Hill.
Fonseca RJ, Marciani RD, Turvey TA 2009 Oral and maxillofacial surgery. Second edition. Saunders.
Kopp S. Akerman S. Nilner 1991(1991) Short-term effects of intra-articular sodium hyaluronate, glucocorticoid, and saline injections on rheumatoid arthritis of the temporomandibular joint.J Craniomandib Disord. 5 231 238.
Alstergren P. Appelgren A. Appelgren B. Kopp S. Lundeberg T. Theodorsson 1996(1996) The effect on joint fluid concentration of neuropeptide Y by intra-articular injection of glucocorticoid in temporomandibular joint arthritis.Acta Odontol Scand. 54 1 7.
Fredriksson L. Alstergren P. Kopp 2005(2005) Serotonergic mechanisms influence the response to glucocorticoid treatment in TMJ arthritis. Mediators Inflamm. 2005 194 201.
Barnes PJ 1998 Anti-inflammatory actions of glucocorticoids: molecular mechanisms.Clin Sci. 94 557 572.
Adcock I. M. Ito K. Barnes P. J. 2004 Glucocorticoids: effects on gene transcription.Proc Am Thorac Soc. 1 247 254.
Gulen H. Ataoglu H. Haliloglu S. Isik 2009(2009) Proinflammatory cytokines in temporomandibular joint synovial fluid before and after arthrocentesis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 107: e 1 4.
Kardel R. Ulfgren A. K. Reinhold F. P. Holmlund 2003K, Reinhold FP, and Holmlund A (2003) Inflammatory cell and cytokine patterns in patients with painful clicking and osteoarthritis in the temporomandibular joint.Int J Oral Maxillofac Surg. 32 390 396.
Nordahl S. Alstergren P. Kopp 2000, Alstergren P, Kopp S (2000) Tumor necrosis factor-alpha in synovial fluid and plasma from patients with chronic connective tissue disease and its relation to temporomandibular joint pain.J Oral Maxillofac Surg. 58 525 530.
Fredriksson L. Alstergren P. Kopp 2006(2006) Tumor necrosis factor- alpha in temporomandibular joint synovial fluid predicts treatment effects on pain by intra-articular glucocorticoid treatment. Mediators Inflamm. 2006: 59425 EOF.
Wenneberg B. Kopp S. Gröndahl H. G. 1991 Long-term effect of intra-articular injections of a glucocorticosteroid into the TMJ: a clinical and radiographic 8-year follow-up.J Craniomandib Disord 5 11 18.
Haddad IK 2000 Temporomandibular joint osteoarthrosis. Histopathological study of the effects of intra-articular injection of triamcinolone acetonide.Saudi Med J. 21 675 679.
Arabshahi B. Dewitt E. M. Cahill A. M. Kaye R. D. Baskin K. M. Towbin R. B. Cron R. Q. 2005 Utility of corticosteroid injection for temporomandibular arthritis in children with juvenile idiopathic arthritis.Arthritis Rheum. 52 3563 3569.
Stoll M. L. Good J. Sharpe T. Beukelman T. Young D. Waite P. D. Cron R. Q. 2012Intra- articular corticosteroid injections to the temporomandibular joints are safe and appear to be effective therapy in children with juvenile idiopathic arthritis. J Oral Maxillofac Surg. (Article in press).
Cahill A. M. Baskin K. M. Kaye R. D. Arabshahi B. Cron R. Q. Dewitt E. M. Bilaniuk L. Towbin R. B. 2007 CT-guided percutaneous steroid injection for management of inflammatory arthropathy of the temporomandibular joint in children.Am J Roentgenol. 188 182 186.
Ringold S. Torgerson T. R. MA Egbert Wallace. CA 2008 Intraarticular corticosteroid injections of the temporomandibular joint in juvenile idiopathic arthritis.J Rheumatol. 35 1157 1164.
Parra D. A. Chan M. Krishnamurthy G. Spiegel L. Amaral J. G. MJ Temple John. P. R. Connolly B. L. 2010 Use and accuracy of US guidance for image-guided injections of the temporomandibular joints in children with arthritis. Pediatr Radiol. 40 1498 1504.
Stoustrup P. Kristensen K. D. Küseler A. Gelineck J. Cattaneo P. M. Pedersen T. K. Herlin 2008K, Herlin T (2008) Reduced mandibular growth in experimental arthritis in the temporomandibular joint treated with intra-articular corticosteroid. Eur J Orthod. 30 111 119.
Schindler C. Paessler L. Eckelt U. Kirch 2005(2005) Severe temporomandibular dysfunction and joint destruction after intra-articular injection of triamcinolone. J Oral Pathol Med. 34 184 186.
El-Hakim IE, 2005bdel-Hamid IS, Bader A (2005) Temporomandibular joint (TMJ) response to intra-articular dexamethasone injection following mechanical arthropathy: a histological study in rats. Int J Oral Maxillofac Surg 34 305 310.
Samiee A, Sabzerou D, Edalatpajouh F, Clark GT, Ram S (2011) Temporomandibular joint injection with corticosteroid and local anesthetic for limited mouth opening. J Oral Sci. 53: 321-325.
MS Greenberg Glick. M. Ship J. A. 2008Burket’s oral medicine. Eleventh edition. Hamilton: BC Decker Inc.
Rodriguez M, Rubio JA, Sanchez R (2007) Effectiveness of two oral pastes for treatment of recurrent aphthous stomatitis. Oral Diseases. 13: 490-494.
Holbrook W. P. Kristmundsdottir T. Loftsson 1998, Loftsson T (1998) Aqueous hydrocortisone mouthwash solution: clinical evaluation. Acta Odontol Scand. 56 157 160.
Lo Muzio. L. Della Valle A. MD Mignogna Pannone. G. Bucci P. Bucci E. Sciubba 2001(2001) The treatment of oral aphthous ulceration or erosive lichen planus with topical clobetasol propionate in three preparations: a clinical and pilot study on 54 patients. J Oral Pathol Med. 30 611 617.
MA Gonzalez-Moles Morales. P. Rodriguez-Archilla A. Isabel I. R. Gonzalez-Moles 2002(2002) Treatment of severe chronic oral erosive lesions with clobetasol propionate in aqueous solution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 93 264 270.
Altenburg A. Zouboulis C. C. 2008 Current concepts in the treatment of recurrent aphthous stomatitis.Skin Therapy Lett. 13 1 4.
Chams-Davatchi C. Esmaili N. Daneshpazhooh M. Valikhani M. Balighi K. Hallaji Z. Barzegari M. Akhyani M. Ghodsi S. Z. Seirafi H. MJ Nazemi Mortazavi. H. Mirshams-Shahshahani 2007, Valikhani M, Balighi K, Hallaji Z, Barzegari M, Akhyani M, Ghodsi SZ, Seirafi H, Nazemi MJ, Mortazavi H, Mirshams-Shahshahani M (2007) Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol. 57 622 628.
Ionnides D. Chrysomallis F. Bystryn J. C. 2000Ineffectiveness of cyclosporine as an adjuvant to corticosteroids in the treatment of pemphigus. Arch Dermatol 136 868 872.
Beissert S. Werfel T. Frieling U. Böhm M. Sticherling M. Stadler R. Zillikens D. Rzany B. Hunzelmann N. Meurer M. Gollnick H. Ruzicka T. Pillekamp H. Junghans V. Luger T. A. 2006A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol 142 1447 1454.
Neff A. G. Turner M. Mutasim D. F. 2008 Treatment strategies in mucous membrane pemphigoid. Ther Clin Risk Manag. 4 617 626.
Michaels 2009(2009) The role of systemic corticosteroid therapy in erythema multiforme major and stevens-johnson syndrome: a review of past and current opinions. J Clin Aesthet Dermatol. 2 51 55.
Kardaun SH, Jonkman MF 2007 Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis.Acta Derm Venereol. 87 144 148.
Patterson R. MS Dykewicz Gonzalzles. A. Grammer L. C. Green D. Greenberger P. A. Mc Grath K. G. Walker C. L. 1990Erythema multiforme and Stevens-Johnson syndrome. Descriptive and therapeutic controversy. Chest. 98 331 336.
Kakourou T. Klontza D. Soteropoulou F. Kattamis 1997(1997) Corticosteroid treatment of erythema multiforme major (Stevens-Johnson syndrome) in children.Eur J Pediatr. 156 90 93.
Martinez AE, Atherton DJ 2000 High-dose systemic corticosteroids can arrest recurrences of severe mucocutaneous erythema multiforme.Pediatr Dermatol. 17 87 90.
Scully C. Bagan 2008(2008) Oral mucosal diseases: erythema multiforme. Br J Oral Maxillofac Surg. 46 90 95.
Schneck J. Fagot J. P. Sekula P. Sassolas B. Roujeau J. C. Mockenhaupt 2008ockenhaupt M (2008) Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol. 58 33 40.
Gauglitz G. G. Korting H. C. Pavicic T. Ruzicka T. Jeschke M. G. 2011 Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies.Mol Med. 17 113 25.
Donkor 2007 Head and neck keloid: treatment by core excision and delayed intralesional injection of steroid. J Oral Maxillofac Surg. 65: 1292-1296.
Gupta S. Sharma V. K. 2011 Standard guidelines of care: Keloids and hypertrophic scars. Indian J Dermatol Venereol Leprol. 77 94 100.
Langston JR, Kolodny SC 1976Cushing’s syndrome associated with the intradermal injection of triamcinolone diacetate. J Oral Surg 34 846 9.
Ritota PC, Lo AK 1996Cushing’s syndrome in postburn children following intralesional triamcinolone injection. Ann Plast Surg 36 508 511.
Ferretti C. Muthray 2011(2011) Management of central giant cell granuloma of mandible using intralesional corticosteroids: case report and review of literature. J Oral Maxillofac Surg. 69 2824 2829.
Sheikh SB, Jacobus 2012(2012) Are steroids effective for treating Bell’s palsy? Ann Emerg Med. 59 33 34.
Sherbino 2010(2010) Evidence-based emergency medicine: clinical synopsis. Do antiviral medications improve recovery in patients with Bell’s palsy?Ann Emerg Med. 55 475 476.
Gilden 2009(2009) Treatment of Bell’s palsy--the pendulum has swung back to steroids alone. Lancet Neurol, 7 976 977.
Mc Grath C. Comfort M. B. Lo E. C. Luo 2003(2003) Changes in life quality following third molar surgery--the immediate postoperative period.Br Dent J. 194 265 8.
Colorado-Bonnin M, Valmaseda-Castellón E, Berini-Aytés L, Gay-Escoda C (2006) Quality of life following lower third molar removal. Int J Oral Maxillofac Surg. 35: 343-347.
Sortino F. Cicciù 2011(2011) Strategies used to inhibit postoperative swelling following removal of impacted lower third molar. Dent Res J (Isfahan). 8 162 171.
Gürlek A. Fariz A. Aydoğan H. Ersöz-Oztürk A. Evans G. R. 2009Effects of high dose corticosteroids in open rhinoplasty. J Plast Reconstr Aesthet Surg. 62 650 655.
Kargı E. Hosnuter M. Babuccu O. Altunkaya H. Altinyazar 2003(2003) Effect of steroids on edema, ecchymosis, and intraoperative bleeding in rhinoplasty. Ann Plast Surg. 51 570 574.
Kara CO, Gokalan 1999(1999) Effects of single-dose steroid usage on edema, ecchymosis, and intraoperative bleeding in rhinoplasty.Plast Reconstr Surg 104 2213 2218.
Hoffmann DF, Cook TA, Quatela VC, Wang TD, Brownrigg PJ, Brummett RE 1991 Steroids and rhinoplasty. A double-blind study.Arch Otolaryngol Head Neck Surg. 117 990 993.
Weber CR, Griffin JM 1994 Evaluation of dexamethasone for reducing postoperative edema and inflammatory response after orthognathic surgery.J Oral Maxillofac Surg. 52 35 9.
Peillon D. Bubost J. Roche C. Bienvenu J. Breton P. Carry P. Y. Freidel M. Banssillon 1996Do corticotherapy and hemodilution decrease postoperative inflammation after maxillofacial surgery?]. Ann Fr Anesth Reanim. 15: 157-61.
Schaberg SJ, Stuller CB, Edwards SM 1984 Effect of methylprednisolone on swelling after orthognathic surgery.J Oral Maxillofac Surg 42 356 361.
Munro IR, Boyd JB, Wainwright DJ 1986 Effect of steroids in maxillofacial surgery.Ann Plast Surg 17 440 444.
Zandi 2008(2008) Comparison of corticosteroids and rubber drain for reduction of sequelae after third molar surgery. Oral Maxillofac Surg. 12 29 33.
Buyukkurt M. C. Gungormus M. Kaya 2006(2006) The effect of a single dose prednisolone with and without diclofenac on pain, trismus and swelling after removal of mandibular third molars.J Oral Maxillofac Surg. 64 1761 1766.
Graziani F. D’Aiuto F. Arduino P. G. Tonelli M. Gabriele 2006, Gabriele M (2006) Perioperative dexamethasone reduces post-surgical sequelae of wisdom tooth removal. A split- randomized double-masked clinical trial. J Oral Maxillofac Surg. 35 241 246.
Esen E. Tasar F. Akhan 1999(1999) Determination of the antiinflammatory effects of methylprednisolone on the sequelae of third molar surgery. J Oral Maxillofac Surg. 57 1201 1206.
Dan AE, Thygesen TH, Pinholt EM 2010 Corticosteroid administration in oral and orthognathic surgery: a systematic review of the literature and meta-analysis. J Oral Maxillofac Surg. 68 2207 2220.
Chi C. C. Wang S. H. Kirtschig G. Wojnarowska 2010(2010) Systematic review of the safety of topical corticosteroids in pregnancy. J Am Acad Dermatol. 62 694 705.
Manson S. C. Brown R. E. Cerulli A. Vidaurre C. F. 2009 The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. Respir Med. 103 975 994.
Dahl 2006(2006) Systemic side effects of inhaled corticosteroids in patients with asthma. Respir Med. 100 1307 1317.
Salem M. Tainsh R. E. Jr Bromberg J. Loriaux D. L. Chernow 1994romberg J, Loriaux DL, Chernow B (1994) Perioperative glucocorticoid coverage. A reassessment 42 years after emergence of a problem.Ann Surg. 219 416 25.
Zandi M. Miresmaeili 2007(2007) Study of the cephalometric features of parents of children with cleft lip and/or palate anomaly. Int J Oral Maxillofac Surg. 36 200 206.
Zandi M. Heidari 2011(2011) An epidemiologic study of orofacial clefts in hamedan city, iran: a 15-year study. Cleft Palate Craniofac J. 48 483 489.
Carmichael S. L. Shaw G. M. Ma Werler C. MM Rasmussen S. A. Lammer E. J. National Birth. Defects Prevention. Study 2007Maternal corticosteroid use and orofacial clefts. Am J Obstet Gynecol. 197: 585.e 1 7.
Pradat P, Robert-Gnansia E, Di Tanna GL, Rosano A, Lisi A, Mastroiacovo P (2003) First trimester exposure to corticosteroids and oral clefts. Birth Defects Res Clin Mol Teratol. 67: 968-970.
Kallen 2003(2003) Maternal drug use and infant cleft lip/palate with special reference to corticoids.Cleft Palate Craniofac J. 40 624 628.
Park-Wyllie L. Mazzotta P. Pastuszak A. ME Moretti Beique. L. Hunnisett L. Friesen M. H. Jacobson S. Kasapinovic S. Chang D. Diav-Citrin O. Chitayat D. Nulman I. Einarson T. R. Koren 2000(2000) Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology. 62 385 392.
MJ Edwards Agho. K. Attia J. Diaz P. Hayes T. Illingworth A. Roddick L. G. 2003 Case-control study of cleft lip or palate after maternal use of topical corticosteroids during pregnancy.Am J Med Genet. 120 459 463.
Turpeinen 1991(1991) Absorption of hydrocortisone from the skin reservoir in atopic dermatitis.Br J Dermatol. 124 358 360.
MJ Edwards Agho. K. Attia J. Diaz P. Hayes T. Illingworth A. Roddick L. G. 2003 Case-control study of cleft lip or palate after maternal use of topical corticosteroids during pregnancy.Am J Med Genet A. 120 459 463.
Blais L. Beauchesne M. F. Lemière C. Elftouh 2009(2009) High doses of inhaled corticosteroids during the first trimester of pregnancy and congenital malformations. J Allergy Clin Immunol. 124 1229 1234.
Goldman AS 1984 Biochemical mechanism of glucocorticoid-and phenytoin-induced cleft palate.Curr Top Dev Biol. 19 217 239.